In a phase 1 trial for a DNA vaccine encoding HER-2/neu for advanced-stage ERBB2-positive breast cancer (NCT00436254), participants aged 34–77 years were immunized three times with one of three dosages (50, 100, or 500ug) (160). Here, ERBB2 is linked to breast cancer.